Bel­licum shares surge as FDA lifts a clin­i­cal hold on lead cell ther­a­py fol­low­ing a pro­to­col ad­just­ment

In­vestors in Hous­ton-based Bel­licum $BLCM can now breathe a sigh of re­lief.

The com­pa­ny re­port­ed Wednes­day evening that the FDA has lift­ed the clin­i­cal hold it dropped on their stud­ies of BPX-501 af­ter amend­ing their tri­al pro­to­cols. The com­pa­ny did not re­veal ex­act­ly what it had to do, but Bel­licum per­formed in line with ex­pec­ta­tions in keep­ing the halt to a rel­a­tive­ly brief spell.

In a new­ly re­leased state­ment, the biotech not­ed:

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.